Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder.

Paris: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...

PENDER COUNTY, N.C. (WECT) - Pender County Mosquito Control is preparing for treatments for the season and is asking beekeepers in the county to help protect their bees. Beekeepers should register the ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to ...

One came in 2023, however, when the FDA rejected it as a treatment for chronic spontaneous urticaria (CSU), asking for more data. Eighteen months later—and backed by more conclusive results ...

In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment TARRYTOWN, N.Y. and PARIS, April 18 ...

“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives,” said ...

Phase 3 trials showed significant reductions in itch and urticaria severity with dupilumab compared to placebo at week 24. Dupilumab offers a new treatment option for CSU, being the first targeted ...

Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older. Several studies reported reduced itch severity and urticaria activity with dupilumab.